Stockscreener 앱 받기
6.34
5.37%
-0.36
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Nuvation Bio Inc (NUVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvation Bio Inc (NUVB) Institutional Confidence - TradingKey
Nuvation Bio Inc (NUVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvation Bio Inc (NUVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvation Bio Inc (NUVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NUVB|Nuvation Bio Inc|Price:6.420|Chg%:-0.055 - TradingKey
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvation Bio Inc. (NUVB) Stock Analysis: A Potential 90% Upside In The Biotech Sector - DirectorsTalk Interviews
Nuvation Bio Inc (NUVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvation Bio to report Q2 2026 results on August 6 - scanx.trade
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential - Investing.com India
Nuvation Bio To Report Second Quarter 2026 Financial Results - TradingView
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says - Moomoo
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential By Investing.com - Investing.com South Africa
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case - Sahm
Frontier tech research, news & data - MLQ.ai
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung - Pharmaceutical Executive
symbol__ Stock Quote Price and Forecast - CNN
Nuvation Bio stock jumps on safusidenib trial expansion plans - Investing.com India
Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com - Investing.com Nigeria
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio - Bitget
NUVB Stock Slides On Financing As Bullish Analysts Double Down - StocksToTrade
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data - Yahoo
Nuvation Bio reports 51.9% response rate for safusidenib in Phase 2 glioma study - grafa.com
Why Is Nuvation Bio Stock Gaining Monday? - Benzinga
Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - Bitget
Nuvation Bio (NUVB) Corporate presentation Summary - Quartr
Nuvation Bio expands safusidenib program with two new studies By Investing.com - Investing.com Nigeria
Nuvation Bio expands safusidenib program with two new studies - Investing.com
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - Investing News Network
NUVB: IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets - TradingView
Form 4 Nuvation Bio Inc For: 17 July By Investing.com - Investing.com South Africa
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
How Nuvation Bio Manages its Ongoing Clinical Trials - Pharmaceutical Executive
Goodwin Advises On Nuvation Bio’s $287.5 Million Registered Convertible Senior Notes Offering With Capped Call - Mondaq
The Status of Nuvation Bio’s Pipeline - Pharmaceutical Executive
Nuvation Bio’s Global Strategy - Pharmaceutical Executive
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo Finance
2.44%
0.02%
자본화:
|
볼륨(24시간):